1. Home
  2. DAKT vs NUVB Comparison

DAKT vs NUVB Comparison

Compare DAKT & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DAKT
  • NUVB
  • Stock Information
  • Founded
  • DAKT 1968
  • NUVB 2018
  • Country
  • DAKT United States
  • NUVB United States
  • Employees
  • DAKT N/A
  • NUVB N/A
  • Industry
  • DAKT Office Equipment/Supplies/Services
  • NUVB Biotechnology: Pharmaceutical Preparations
  • Sector
  • DAKT Industrials
  • NUVB Health Care
  • Exchange
  • DAKT Nasdaq
  • NUVB Nasdaq
  • Market Cap
  • DAKT 710.0M
  • NUVB 679.9M
  • IPO Year
  • DAKT 1994
  • NUVB N/A
  • Fundamental
  • Price
  • DAKT $16.86
  • NUVB $2.55
  • Analyst Decision
  • DAKT Strong Buy
  • NUVB Strong Buy
  • Analyst Count
  • DAKT 1
  • NUVB 6
  • Target Price
  • DAKT $26.00
  • NUVB $7.83
  • AVG Volume (30 Days)
  • DAKT 375.7K
  • NUVB 5.5M
  • Earning Date
  • DAKT 09-03-2025
  • NUVB 08-04-2025
  • Dividend Yield
  • DAKT N/A
  • NUVB N/A
  • EPS Growth
  • DAKT N/A
  • NUVB N/A
  • EPS
  • DAKT N/A
  • NUVB N/A
  • Revenue
  • DAKT $756,477,000.00
  • NUVB $10,957,000.00
  • Revenue This Year
  • DAKT $9.98
  • NUVB $98.78
  • Revenue Next Year
  • DAKT $6.80
  • NUVB $489.71
  • P/E Ratio
  • DAKT N/A
  • NUVB N/A
  • Revenue Growth
  • DAKT N/A
  • NUVB N/A
  • 52 Week Low
  • DAKT $10.24
  • NUVB $1.54
  • 52 Week High
  • DAKT $19.89
  • NUVB $3.97
  • Technical
  • Relative Strength Index (RSI)
  • DAKT 64.04
  • NUVB 65.10
  • Support Level
  • DAKT $15.84
  • NUVB $2.46
  • Resistance Level
  • DAKT $16.72
  • NUVB $2.62
  • Average True Range (ATR)
  • DAKT 0.44
  • NUVB 0.16
  • MACD
  • DAKT -0.00
  • NUVB 0.04
  • Stochastic Oscillator
  • DAKT 85.36
  • NUVB 69.29

About DAKT Daktronics Inc.

Daktronics Inc designs and manufactures electronic scoreboards, programmable display systems, and large-screen video displays for sporting, commercial, and transportation applications. It is engaged in a full range of activities: marketing and sales, engineering and product design and development, manufacturing, technical contracting, professional services, and customer service and support. The company offers a complete line of products, from small scoreboards and electronic displays to large multimillion-dollar video display systems as well as related control, timing, and sound systems. The company has five reportable segments: Commercial, Live Events, High School Park and Recreation, Transportation, and International. The company makes the majority of its revenue from Live events.

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).

Share on Social Networks: